PaTu 8988tHomo sapiens (Human)Cancer cell line

Also known as: PaCL4, 8988T, PA-TU T, PATU-T, PATU-8988T, PaTu-8988t, PaTu 8988 T, PATU8988T, PaTu8988T, PaTu8988t, PA-TU-8988T

🤖 AI SummaryBased on 12 publications

Quick Overview

Pancreatic cancer cell line with genomic alterations and metabolic subtypes.

Detailed Summary

PaTu 8988t is a pancreatic cancer cell line characterized by specific genomic alterations, including amplifications and deletions identified through array-based comparative genomic hybridization (aCGH). These alterations include regions on chromosomes 8q23-24, 12p11-12, and 18q23, which are associated with oncogenic processes. The cell line also exhibits distinct metabolic subtypes, showing differences in glycolytic and lipogenic pathways, which may influence its response to metabolic inhibitors. Research on PaTu 8988t has contributed to understanding the heterogeneity of pancreatic cancer and the development of targeted therapies.

Research Applications

Genomic alterations analysisMetabolic profilingDrug sensitivity testing

Key Characteristics

Amplifications in 8q23-24 and 12p11-12Deletions in 18q23Distinct metabolic subtypes

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1847
Species	Homo sapiens (Human)
Tissue Source	Liver[UBERON:UBERON_0002107]

Donor Information

Age	64
Age Category	Adult
Sex	Female

Disease Information

Disease	Pancreatic adenocarcinoma
Lineage	Pancreas
Subtype	Pancreatic Adenocarcinoma
OncoTree Code	PAAD

DepMap Information

Source Type	DSMZ
Source ID	ACH-000023_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Arg282Trp (c.844C>T)	Unspecified	-	PubMed=21173094, PubMed=1373872
MutationSimple	KRAS	p.Gly12Val (c.35G>T)	Heterozygous	Acquired	Unknown, Unknown
MutationUnexplicit	EP300	Ex17-19del (c.4342del448)	Homozygous	-	PubMed=10700188
Gene deletion	SMAD4	-	Homozygous	-	from parent cell line BxPC-3

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

CSF1PO

11,13

D13S317

12,13

D16S539

11,12

D18S51

D19S433

14,15

D21S11

D2S1338

D3S1358

15,17

D5S818

11,13

D7S820

7,8

D8S1179

13,16

FGA

Penta D

Penta E

TH01

TPOX

8,11

vWA

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOI PubMed PMC

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

DOI PubMed PMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOI PubMed PMC

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

DOI PubMed

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

DOI PubMed PMC

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOI PubMed PMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOI PubMed PMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOI PubMed PMC

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.

Manning G., Settleman J., Hatzivassiliou G., Evangelista M.

Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).

DOI PubMed PMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOI PubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOI PubMed

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.

Linnartz R., Zubel A., Slamon D.J., Finn R.S.

Br. J. Cancer 111:1788-1801(2014).

DOI PubMed PMC

Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Rottapel R., Neel B.G., Moffat J.

Cancer Discov. 2:172-189(2012).

DOI PubMed PMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOI PubMed PMC

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOI PubMed PMC

Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications.

Gorunova L., van Kessel A.G., Schoenmakers E.F.P.M., Hoglund M.

Oncogene 24:1794-1801(2005).

DOI PubMed

Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines.

Veltman J.A., van Kessel A.G., Hoglund M.

Cancer Res. 64:3052-3059(2004).

DOI PubMed

Immunocytochemical analysis of cell lines derived from solid tumors.

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

J. Histochem. Cytochem. 49:1369-1378(2001).

DOI PubMed

Mutations truncating the EP300 acetylase in human cancers.";

Delhanty J.D.A., Ponder B.A.J., Kouzarides T., Caldas C.

Nat. Genet. 24:300-303(2000).

DOI PubMed

Higher frequency of DPC4/Smad4 alterations in pancreatic cancer cell lines than in primary pancreatic adenocarcinomas.

Chaloupka B., Deiss Y., Simon B., Schudy A.

Cancer Lett. 139:43-49(1999).

DOI PubMed

Establishment and characterisation of two cell lines with different grade of differentiation derived from one primary human pancreatic adenocarcinoma.

Elsasser H.-P., Lehr U., Agricola B., Kern H.F.

Virchows Arch. B. Cell. Pathol. Incl. Mol. Pathol. 61:295-306(1992).

DOI PubMed

Distribution of characteristic mutations in native ductal adenocarcinoma of the pancreas and pancreatic cancer cell lines.

Saeger H.-D.

Cell Biol. Res. Ther. 2:1000104.1-1000104.5(2013).

DOI

Web Resources

dpsc.ccbr.utoronto.ca genome.ucsc.edu tcpaportal.org